What is HC Wainwright’s Estimate for ALGS Q1 Earnings?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) – Equities researchers at HC Wainwright lowered their Q1 2026 earnings estimates for shares of Aligos Therapeutics in a report issued on Wednesday, March 11th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($2.53) per share for the quarter, down from their previous forecast of ($2.36). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Aligos Therapeutics’ current full-year earnings is ($10.36) per share. HC Wainwright also issued estimates for Aligos Therapeutics’ Q2 2026 earnings at ($2.59) EPS, Q3 2026 earnings at ($1.72) EPS, Q4 2026 earnings at ($1.76) EPS, FY2026 earnings at ($8.25) EPS, FY2027 earnings at ($4.06) EPS, FY2028 earnings at ($3.02) EPS, FY2029 earnings at ($2.61) EPS and FY2030 earnings at ($1.06) EPS.

A number of other analysts also recently issued reports on the company. UBS Group initiated coverage on Aligos Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $20.00 price objective on the stock. Wall Street Zen downgraded Aligos Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $35.00.

Aligos Therapeutics Trading Up 2.2%

Shares of Aligos Therapeutics stock opened at $7.57 on Monday. The firm has a market cap of $46.86 million, a PE ratio of -0.88 and a beta of 2.67. The stock has a 50 day moving average of $7.68 and a 200 day moving average of $8.96. Aligos Therapeutics has a 12 month low of $3.76 and a 12 month high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last issued its earnings results on Thursday, March 5th. The company reported ($1.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.09) by $0.18. The firm had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.27 million. Aligos Therapeutics had a negative return on equity of 28.16% and a negative net margin of 1,106.72%.

Institutional Trading of Aligos Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. NorthCrest Asset Manangement LLC purchased a new position in shares of Aligos Therapeutics during the third quarter valued at approximately $98,000. Susquehanna International Group LLP purchased a new stake in shares of Aligos Therapeutics in the third quarter worth approximately $99,000. HRT Financial LP bought a new stake in shares of Aligos Therapeutics during the 4th quarter worth approximately $106,000. DRW Securities LLC bought a new stake in shares of Aligos Therapeutics during the 4th quarter worth approximately $111,000. Finally, XTX Topco Ltd purchased a new position in Aligos Therapeutics during the 2nd quarter valued at $100,000. Institutional investors own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.